Invention Grant
![N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors](/docs/US/2019-09-03/US10399974B2/abs.jpg.600x600.jpg)
- Patent Title: N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
-
Application No.: US15861287Application Date: 2018-01-03
-
Publication No.: US10399974B2Publication Date: 2019-09-03
- Inventor: Hannah Woodward , Paolo Innocenti , Sebastien Naud , Julian Blagg , Swen Hoelder
- Applicant: Cancer Research Technology Limited
- Applicant Address: GB London
- Assignee: Cancer Research Technology Limited
- Current Assignee: Cancer Research Technology Limited
- Current Assignee Address: GB London
- Agency: Foley Hoag LLP
- Agent David P. Halstead; Lucas P. Watkins
- Priority: GB1403536.4 20140228
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D471/04 ; C07D519/00
![N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors](/abs-image/US/2019/09/03/US10399974B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Public/Granted literature
- US20180194761A1 N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS Public/Granted day:2018-07-12
Information query
IPC分类:
